EMA Authorised: Opzelura (ruxolitinib phosphate) — Incyte Biosciences Distribution B.V.

View source ↗

Summary

The EMA has authorised Opzelura (ruxolitinib phosphate) for a therapeutic area focusing on vitiligo, with Incyte Biosciences Distribution B.V. as the marketing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• Opzelura (ruxolitinib)

Snippet

Status: Authorised. Therapeutic area: Vitiligo. MAH: Incyte Biosciences Distribution B.V.. Decision date: 15/06/2026